DEVON, Pa., Oct. 6, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticalsinc CYNEthe leading provider of innovative pharmaceutically manufactured transdermal cannabinoid therapies for rare neuropsychiatric disorders, announced today that the U.S. Patent and Trademark Office has granted Patent No. 11,458,110, entitled “Treatment of Fragile X Syndrome with Cannabidiol,” which Contains claims relating to methods of treating fragile X syndrome with cannabidiol.

This new patent, which expires in 2038, is part of a growing international intellectual property portfolio covering the Company’s transdermal cannabidiol product candidate, Zygel. There are currently four corresponding US patents and one corresponding EU patent relating to methods of treating Fragile X Syndrome.

About Zygel

Zygel is the first and only pharmaceutically manufactured cannabidiol formulated as a proprietary, permeation-enhanced, clear gel designed for controlled transdermal delivery of drugs into the bloodstream (i.e., through the skin). Recent studies suggest that cannabidiol may modulate the endocannabinoid system and improve certain behavioral symptoms associated with neuropsychiatric disorders. Zygel is an investigational drug in development for the potential treatment of behavioral symptoms associated with Fragile X Syndrome (FXS), 22q11.2 Deletion Syndrome (22q) and Autism Spectrum Disorder (ASD). The Company has received Orphan Drug Designation from the FDA and the European Commission for the treatment of FXS and from the FDA for the treatment of 22q for cannabidiol, the active ingredient in Zygel. In addition, Zygel has been designated as a fast-track development program to treat behavioral symptoms of FXS.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is a leader in innovative pharmaceutically manufactured transdermal cannabinoid therapies for rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with serious,…